A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors (MTAP)

  • End date
    Nov 14, 2026
  • participants needed
  • sponsor
Updated on 15 October 2022


The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.

The primary objective of Part 3 of this study is to evaluate the objective response rate (ORR) of AMG 193 in adult participants with metastatic or locally advanced MTAP-null non-small cell lung cancer (NSCLC), after prior treatment with chemotherapy and/or a programmed death-1/ligand 1 (PD-1/L1) inhibitor.

Condition Advanced MTAP-null Solid Tumors
Treatment docetaxel, AMG 193
Clinical Study IdentifierNCT05094336
Last Modified on15 October 2022


Yes No Not Sure

Inclusion Criteria

Participant has provided informed consent/assent before initiation of any study specific activities/procedures
Age ≥ 18 years
Evidence of homozygous loss of cyclin dependent kinase inhibitor 2A (CDKN2A) (null) and/or methylthioadenosine phosphorylase (MTAP) (null) or lost MTAP expression in the tumor tissue
Histologically confirmed metastatic or locally advanced solid tumor not amenable to curative treatment with surgery and/or radiation
Able to swallow and retain orally (PO) administered study treatment and willing to record daily adherence to investigational product
Disease measurable as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Adequate hematopoietic function per local laboratory
Adequate renal function per local laboratory
Adequate glucose control per local laboratory (Part 1 only)
Adequate liver function per local laboratory
Adequate coagulation parameters
Adequate pulmonary function
Adequate cardiac function
Minimum life expectancy of 12 weeks as per investigator judgement
Tumor tissue must be available

Exclusion Criteria

Spinal cord compression or active brain metastases or leptomeningeal disease from non-brain tumors
Presence of primary brain cancer
Presence of hematological malignancy or lymphoma
History of other malignancy within the past 2 years
Evidence of lung disease
Active infection
History of arterial thrombosis
Myocardial infarction and/or symptomatic congestive heart failure, unstable angina, or cardiac arrhythmia
Gastrointestinal tract disease
History of solid organ transplant
Diagnosis of Congenital Short QT Syndrome
Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor
Prior irradiation to greater than 25% of the bone marrow
Unresolved toxicity from prior anti-cancer therapy
Currently receiving treatment in another investigational device or drug study
Known positive test for Human Immunodeficiency Virus
Evidence of hepatitis B or C infection
Female participants of childbearing potential with a positive pregnancy test
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note